Philip Gehrman of the Perelman School of Medicine shares his thoughts on a new study about sleepwalking.
Ben Voight of the Perelman School of Medicine is mentioned as co-author of a study about HDL levels.
Media Contact:Colby Bishop | email@example.com | 202-828-8075May 17, 2012
A team from the Perelman School of Medicine and the Abramson Family Cancer Research Institute at the University of Pennsylvania found that the FDA-approved drug daclizumab improved the survival of breast cancer patients taking a cancer vaccine by 30 percent, compared to those patients not taking daclizumab. This proof-of-concept study is published this week in Science Translational Medicine.
A new study published by researchers at the Perelman School of Medicine at the University of Pennsylvania, the Broad Institute, and Massachusetts General Hospital, challenges the conventional concept that raising a person's HDL levels (good cholesterol) will always help lower their risk of a heart attack.
Media Contact:Jessica Mikulski | Jessica.firstname.lastname@example.org | 215-349-8360May 9, 2012
The American Heart Association (AHA) announced today that they have made their first investment through the Science & Technology Accelerator Program into CytoVas, LLC. The company was founded by Jonni S.
PHILADELPHIA — Targeted drug delivery is one of the more enticing applications of nanotechnology; by designing pharmaceuticals on an atomic scale, engineers hope to get them attacking diseases with newfound precision and efficiency.
A team of University of Pennsylvania researchers has recently been recognized by the National Science Foundation for the development of computer models that will be instrumental in improving these designs.
Media Contact:Kat Stein | email@example.com | 215-898-9642May 16, 2012
Perelman School of Medicine at the University of Pennsylvania researchers have discovered a mechanism involving the neurotransmitter dopamine that switches fruit fly behavior from being active during the day (diurnal) to nocturnal. This change parallels a human disorder in which increased agitation occurs in the evening hours near sunset and may also be due to higher than normal dopamine levels in the brain. Sundown syndrome occurs in older people with dementia or cognitive impairment.